Company Profile
LH insider trades (13 months) →Today's multi-factor rank: 259 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
Labcorp Holdings Inc. (LH) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| 8-K | 2026-09-10 | View filing ↗ |
| 8-K | 2026-08-28 | View filing ↗ |
| 8-K | 2026-08-17 | View filing ↗ |
| 8-K | 2026-08-14 | View filing ↗ |
| 10-Q | 2026-08-05 | View filing ↗ |
| 8-K | 2026-07-30 | View filing ↗ |
| 8-K | 2026-07-10 | View filing ↗ |
| 8-K | 2026-06-30 | View filing ↗ |
| 8-K | 2026-05-27 | View filing ↗ |
| 8-K | 2026-05-26 | View filing ↗ |
Company and Executive Profile
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Adam H. Schechter | President, CEO & Chairman | 60 | 4.18M |
| Ms. Julia A. Wang | CFO & Executive VP | 53 | 1.68M |
| Dr. Brian J. Caveney J.D., M.D., M.P.H. | Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer | 51 | 1.49M |
| Mr. Jonathan C. Meltzer Ph.D. | EVP & Chief Operations Officer | - | - |
| Mr. Peter J. Wilkinson | Senior VP & Chief Accounting Officer | 54 | - |
| Mr. Akinbolade Oyegunwa M.B.A., Ph.D. | Executive VP and Chief Information & Technology Officer | 42 | - |
| Mr. Dewey Steadman C.F.A. | Senior Vice President of Investor Relations | - | - |
| Ms. Kathryn Wright Kyle | Executive VP, Chief Legal Officer and Corporate Secretary | 54 | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.